

Category : Study conduct
Title : Contact and communication with sponsor
SOP No. : D 21/06
Date first effective: 01 Jan 2024 **Review date:** 31 Dec 2024

Department of Clinical Pharmacology, First Floor, New MS Building,
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

Category: Study conduct
Title: Contact and communication with sponsor
SOP No.: D 21/06 **Total pages:** 05

Date first effective: 01 Jan 2024 **Next Review date:** 31 Dec 2024

Version: 06

SOP team:
Author: Dr. Vinayak A.
DM Resident

Signature with date *vinayak A* 23/Dec/2023

Reviewer: Dr. Mahesh Belhekar
Associate Professor

Signature with date *Bel* 26/DEC/2023 · **Dr. Mahesh N. Belhekar**
Associate Professor
Department of Clinical Pharmacology
New MS Building, First Floor,
Seth GS Medical College and KEM Hospital
Acyarya Donde Marg, Parel,
Mumbai- 400 012, India.

Approved by: Dr. Nithya Gogtay
Professor and Head

Signature with date *NG* 31-12-23
Dr. Nithya Gogtay
Professor & Head
Department of Clinical Pharmacology
1st Floor, MS Building,
Seth GS Medical College & KEM Hospital,
Parel, Mumbai - 400 012.

Category : Study conduct
Title : Contact and communication with sponsor
SOP No. : D 21/06
Date first effective: 01 Jan 2024 **Review date:** 31 Dec 2024

Department of Clinical Pharmacology, First Floor, New MS Building,
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

Table of Contents

S.L. No.	Contents	Page No.
1	Purpose	3
2	Scope	3
3	Responsibility	3
4	Applicable rules, regulations, and guidelines	3
5	Reference to other applicable SOPs	3
6	Detailed instructions	4
7	Abbreviations	5

Category : Study conduct
Title : Contact and communication with sponsor
SOP No. : D 21/06
Date first effective: 01 Jan 2024 **Review date:** 31 Dec 2024

Department of Clinical Pharmacology, First Floor, New MS Building,
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

1. Purpose

The purpose of this standard operating procedure (SOP) is to instruct the study team in communication with the sponsor.

2. Scope

This SOP applies to all forms of communications on the site (email, telephone, fax etc.) with the sponsor.

3. Responsibilities

Principal investigator (PI), Co-Investigator (Co-I), study coordinator or the delegated study team members will be responsible for communication with the sponsor.

4. Applicable rules, regulations and guidelines

- New Drugs and Clinical Trials Rules 2019
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/NewDrugs_CTRules_2019.pdf
- National Ethical Guidelines for Biomedical and Health Research involving Human Participants ICMR, 2017
https://www.indiascienceandtechnology.gov.in/sites/default/files/file-uploads/guidelineregulations/1527507675_ICMR_Ethical_Guidelines_2017.pdf
- ICH-GCP E6 (R3) Draft Guidelines dated 19th May 2023
https://database.ich.org/sites/default/files/ICH_E6%28R3%29_DraftGuideline_2023_0519.pdf.

5. Reference to other applicable SOPs

- SOP No. D 17/06: Continued interaction with the Institutional Ethics Committees
- SOP No. D 15/06: Serious Adverse Event (SAE) Monitoring, Recording and Reporting
- SOP No. D 2A/06: Preparing the site team for a clinical study sponsored by pharmaceutical company.

Category : Study conduct
Title : Contact and communication with sponsor
SOP No. : D 21/06
Date first effective: 01 Jan 2024 **Review date:** 31 Dec 2024

Department of Clinical Pharmacology, First Floor, New MS Building,
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

6. Detailed Instructions

- 6.1. The PI will be responsible for the initial communication with the sponsor.
- 6.2. PI or Co-I inform the sponsor about the study team and keeps the sponsor updated on the changes in the study team in the course of the trial.
- 6.3. The PI or a Co-I delegate routine communication to the study coordinator on updates, document submissions and receipt.
- 6.4. Communications pertaining to financial, technical, and regulatory aspects should be done only by the PI or Co-I unless otherwise instructed.
- 6.5. If the sponsor/s collaborate with Contract Research Organization (CRO) for any study, majority of the communication will be done with the CRO. However, specific aspects may be communicated with the sponsor/s as well as CRO and have to be decided a-priori.
- 6.6. Any telephonic conversation should be immediately transcribed to the emails and will be communicated to all the members of the study team and sponsor/s and CRO (if relevant)
- 6.7. All the emails should be acknowledged by the study team members.
- 6.8. All the study members should be kept in the email loop to keep them updated.
- 6.9. All the study team members should be objective, precise, polite, and professional in all communication with the sponsor/s.
- 6.10. Etiquette should always be maintained in the communication. e.g. Doctor XYZ should be addressed as Dear Dr. XYZ.
- 6.11. The study team members will put a "Vacation reply" mentioning the dates and duration of absence, date of resumption and backup person's name, email, and mobile number during the absence.
- 6.12. All important communications should be documented in printed form and kept in the trial master file.
- 6.13. Sponsor should be updated at specified intervals [depending on the SOP of the sponsor] about the progress of the trial through formal email.
- 6.14. During all the phases of the trial, scanned documents of relevant Institutional Ethics Committee communications should be conveyed through formal email.

Category : Study conduct
Title : Contact and communication with sponsor
SOP No. : D 21/06
Date first effective: 01 Jan 2024 **Review date:** 31 Dec 2024

Department of Clinical Pharmacology, First Floor, New MS Building,
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

7. Abbreviations:

- i. Co-I : Co-Investigator
- ii. CRO : Contract Research Organization
- iii. PI : Principal investigator
- iv. SOP : Standard Operating Procedure
- v. GCP : Good Clinical Practice
- vi. ICH : International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use
- vii. ICMR : Indian Council of Medical Research
- viii. IEC : Institutional Ethics Committee

Reviewer: Dr. Mahesh Belhekar
Associate Professor

Signature with date

Belh
26/DEC/2023

Dr. Mahesh N. Belhekar
Associate Professor
Department of Clinical Pharmacology
New MS Building, First Floor,
Seth GS Medical College and KEM Hospital
Acyarya Donde Marg, Parel,
Mumbai- 400 012, India.

Approved by: Dr. Nithya Gogtay
Professor and Head

Signature with date

31.12.23
Dr. Nithya Gogtay
Professor & Head
Department of Clinical Pharmacology
1st Floor, MS Building,
Seth GS Medical College & KEM Hospital,
Parel, Mumbai - 400 012.